CA2680106A1 - Compositions de docetaxel nanoparticulaires sterilisees par rayonnement gamma et procedes de fabrication associes - Google Patents

Compositions de docetaxel nanoparticulaires sterilisees par rayonnement gamma et procedes de fabrication associes Download PDF

Info

Publication number
CA2680106A1
CA2680106A1 CA002680106A CA2680106A CA2680106A1 CA 2680106 A1 CA2680106 A1 CA 2680106A1 CA 002680106 A CA002680106 A CA 002680106A CA 2680106 A CA2680106 A CA 2680106A CA 2680106 A1 CA2680106 A1 CA 2680106A1
Authority
CA
Canada
Prior art keywords
docetaxel
less
composition
group
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002680106A
Other languages
English (en)
Inventor
H. William Bosch
Janine Keller
Niels Ryde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Co PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Publication of CA2680106A1 publication Critical patent/CA2680106A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
CA002680106A 2007-03-23 2008-03-20 Compositions de docetaxel nanoparticulaires sterilisees par rayonnement gamma et procedes de fabrication associes Abandoned CA2680106A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89664707P 2007-03-23 2007-03-23
US60/896,647 2007-03-23
PCT/US2008/057701 WO2008118754A2 (fr) 2007-03-23 2008-03-20 Compositions de docétaxel nanoparticulaires stérilisées par rayonnement gamma et procédés de fabrication associés

Publications (1)

Publication Number Publication Date
CA2680106A1 true CA2680106A1 (fr) 2008-10-02

Family

ID=39789241

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002680106A Abandoned CA2680106A1 (fr) 2007-03-23 2008-03-20 Compositions de docetaxel nanoparticulaires sterilisees par rayonnement gamma et procedes de fabrication associes

Country Status (4)

Country Link
EP (1) EP2139470A4 (fr)
JP (1) JP2010522207A (fr)
CA (1) CA2680106A1 (fr)
WO (1) WO2008118754A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027644A2 (fr) * 2007-08-24 2009-03-05 Stichting Het Nederlands Kanker Instituut Composition
US9089544B2 (en) 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
TWI558422B (zh) 2009-05-27 2016-11-21 阿艾克麥斯製藥愛爾蘭有限公司 減少奈米顆粒活性劑組成物中薄片狀聚集之技術
DE102010047702A1 (de) 2009-11-04 2011-05-05 Merck Patent Gmbh Verbindung für ein flüssigkristallines Medium und deren Verwendung für Hochfrequenzbauteile
CN115919815A (zh) 2017-06-14 2023-04-07 克里蒂泰克公司 治疗肺部疾病的方法
EP3796951A4 (fr) * 2018-05-19 2021-07-07 Gary Binyamin Formulations de mousse et procédés d'administration au corps
CN114712316B (zh) * 2020-12-18 2023-10-20 江苏恒瑞医药股份有限公司 一种难溶性药物组合物及制备方法
US20230024844A1 (en) * 2021-04-29 2023-01-26 Protara Therapeutics, Inc. Sterile aqueous choline salt compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
CA2302699A1 (fr) * 1997-08-21 1999-02-25 Florida State University Procede de synthese de taxanes
GB9820457D0 (en) * 1998-09-18 1998-11-11 Medlogic Global Corp Methods for sterilizing cyanoacrylate compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20020141966A1 (en) * 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same
CA2500908A1 (fr) * 2002-10-04 2004-04-22 Elan Pharma International Limited Irradiation gamma d'agents actifs nanoparticulaires solides
EP1855659A2 (fr) * 2005-02-24 2007-11-21 Elan Pharma International Limited Preparations de nanoparticules de docetaxel et de ses analogues

Also Published As

Publication number Publication date
WO2008118754A3 (fr) 2009-12-30
WO2008118754A2 (fr) 2008-10-02
EP2139470A2 (fr) 2010-01-06
EP2139470A4 (fr) 2010-07-28
JP2010522207A (ja) 2010-07-01

Similar Documents

Publication Publication Date Title
US20080220074A1 (en) Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
EP1427395B1 (fr) Stabilisation d'agents actifs par formulation sous forme nanoparticulaire
US20060188566A1 (en) Nanoparticulate formulations of docetaxel and analogues thereof
CA2680106A1 (fr) Compositions de docetaxel nanoparticulaires sterilisees par rayonnement gamma et procedes de fabrication associes
AU2005316473B2 (en) Nanoparticulate tacrolimus formulations
US20090238867A1 (en) Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
JP4842514B2 (ja) 血管新生抑制剤のナノ粒子組成物
ES2365012T3 (es) Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano.
KR20080105114A (ko) 나노입자형 카르베디롤 제제
MX2007015309A (es) Formulaciones de mesilato de imatinib en nanoparticulas.
NZ546063A (en) Controlled release sterile injectable aripiprazole (7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-butoxy]-3,4-dihydro-2(1H)-quinolinone) formulation and method
EP2279727A2 (fr) Formulations nanoparticulaires d'aripiprazole
FR2945950A1 (fr) Compositions de nanoparticules anticancereuses et procedes pour les preparer
US20110159054A1 (en) Nanoparticulate bicalutamide formulations
JP2018199685A (ja) インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
WO2011158052A1 (fr) Compositions d'ézétimibe nanostructurées, leur procédé de préparation, et compositions pharmaceutiques les contenant
CN115776881A (zh) 长效配制品

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20130320